Table 4 Pharmacokinetic parameters of THQ-PLGA-NPs after i.n. and i.v. administration to rats at the dose of 10 mg kg−1 in brain, lungs and plasma (n = 6, mean ± SD)
Formulation administration | Samples | Cmax (ng/mL g) | Tmax | t1/2 (h) | Ke (h−1) | AUC0–t (ng min/mL g) |
|---|---|---|---|---|---|---|
THQ-S (i.n.) | Brain | 29.46 ± 1.67 | 2.00 | 8.22 ± 0.75 | 0.0843 ± 0.009 | 251.08 ± 15.97 |
Lungs | 14.89 ± 0.96 | 2.00 | 20.61 ± 1.08 | 0.0336 ± 0.0021 | 186.30 ± 20.10 | |
Plasma | 12.89 ± 0.64 | 0.5 | 5.61 ± 0.57 | 0.1237 ± 0.0021 | 53.07 ± 1.56 | |
THQ-S (i.v.) | Brain | 19.17 ± 0.88 | 2.00 | 10.43 ± 0.46 | 0.0664 ± 0.0011 | 145.68 ± 10.09 |
Lungs | 12.09 ± 0.76 | 2.00 | 11.95 ± 1.00 | 0.0580 ± 0.0011 | 130.47 ± 9.95 | |
Plasma | 491.01 ± 11.19 | 1.00 | 7.74 ± 0.24 | 0.0895 ± 0.0031 | 3832.45 ± 121.08 | |
THQ-PLGA-NPs (i.n.) | Brain | 445.94 ± 8.67 | 2.00 | 87.98 ± 12.46 | 0.0079 ± 0.00009 | 6942.67 ± 109.89 |
Lungs | 102.01 ± 7.68 | 2.00 | 15.29 ± 1.87 | 0.0453 ± 0.0006 | 776.63 ± 28.89 | |
Plasma | 23.01 ± 1.87 | 2.00 | 13.07 ± 2.67 | 0.0530 ± 0.0021 | 260.64 ± 28.06 | |
THQ-PLGA-NPs (i.v.) | Brain | 109.84 ± 9.01 | 2.00 | 11.29 ± 1.67 | 0.0614 ± 0.0035 | 1154.31 ± 78.01 |
Lungs | 91.01 ± 4.66 | 2.00 | 23.12 ± 2.09 | 0.0300 ± 0.0048 | 800.12 ± 34.11 | |
Plasma | 453.93 ± 16.01 | 1.00 | 9.21 ± 0.96 | 0.0753 ± 0.0014 | 3675.41 ± 98.95 | |
TQ (i.n.) | Brain/plasma | 2.29 | 4.00 | 1.47 | 0.68 | 4.73 |
TQ (i.v.) | Brain/plasma | 0.03 | 2.00 | 1.35 | 0.74 | 0.04 |
THQ-PLGA-NPs (i.n.) | Brain/plasma | 19.38 | 1.00 | 6.73 | 0.15 | 26.64 |
THQ-PLGA-NPs (i.v.) | Brain/plasma | 0.24 | 1.00 | 1.23 | 0.82 | 0.32 |